BR112013030991A2 - uso de gdc-0980 e método de tratamento de mesotelioma - Google Patents

uso de gdc-0980 e método de tratamento de mesotelioma

Info

Publication number
BR112013030991A2
BR112013030991A2 BR112013030991A BR112013030991A BR112013030991A2 BR 112013030991 A2 BR112013030991 A2 BR 112013030991A2 BR 112013030991 A BR112013030991 A BR 112013030991A BR 112013030991 A BR112013030991 A BR 112013030991A BR 112013030991 A2 BR112013030991 A2 BR 112013030991A2
Authority
BR
Brazil
Prior art keywords
gdc
treatment method
mesothelioma treatment
mesothelioma
treatment
Prior art date
Application number
BR112013030991A
Other languages
English (en)
Inventor
Jennifer O Hara Lauchle
Mika K Derynck
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112013030991A2 publication Critical patent/BR112013030991A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
BR112013030991A 2011-06-03 2012-06-01 uso de gdc-0980 e método de tratamento de mesotelioma BR112013030991A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161492966P 2011-06-03 2011-06-03
PCT/EP2012/060341 WO2012164060A1 (en) 2011-06-03 2012-06-01 Methods of treating mesothelioma with a pi3k inhibitor compound

Publications (1)

Publication Number Publication Date
BR112013030991A2 true BR112013030991A2 (pt) 2016-11-29

Family

ID=46210240

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013030991A BR112013030991A2 (pt) 2011-06-03 2012-06-01 uso de gdc-0980 e método de tratamento de mesotelioma

Country Status (11)

Country Link
US (1) US20120308562A1 (pt)
EP (1) EP2714046A1 (pt)
JP (1) JP2014515390A (pt)
KR (1) KR20140040728A (pt)
CN (1) CN103582479A (pt)
AR (1) AR086647A1 (pt)
BR (1) BR112013030991A2 (pt)
CA (1) CA2835760A1 (pt)
MX (1) MX2013014151A (pt)
RU (1) RU2013154355A (pt)
WO (1) WO2012164060A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103313989B (zh) 2010-12-16 2016-05-04 霍夫曼-拉罗奇有限公司 三环pi3k抑制剂化合物和使用方法
BR112015007970A8 (pt) 2012-10-10 2019-08-27 Hoffmann La Roche processo de preparação de (s)-1-(4-((2-(2-aminopirimidin-5-il)-7-metil-4-morfolinotieno[3,2-d]pirimidin-6-il)metil)piperazin-1-il)-2-hidroxipropan-1-ona e sal de oxalato de (s)-2-hidróxi-1- (piperazin-1-il)propan-1-ona
KR20160013092A (ko) * 2013-05-23 2016-02-03 파이브 프라임 테라퓨틱스, 인크. 암을 치료하는 방법
CA2912627C (en) * 2013-05-29 2022-03-15 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
SG10201913080VA (en) * 2013-12-12 2020-03-30 Almirall Sa Pharmaceutical compositions comprising dimethyl fumarate
BR112017008290A2 (pt) * 2014-10-30 2017-12-19 Big Dna Ltd terapia de combinação
KR20180021814A (ko) * 2015-06-30 2018-03-05 제넨테크, 인크. 약물을 포함하는 속방성 정제 및 상기 정제의 형성 공정
EP3641736A1 (en) 2017-06-23 2020-04-29 Almirall, S.A. Pharmaceutical compositions comprising dimethyl fumarate
US11103594B2 (en) 2018-02-01 2021-08-31 Imam Abdulrahman Bin Faisal University Hierarchical siliceous mesosilicalite nanocarrier loaded with platinum(II) complex

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
DK1934174T3 (da) 2005-10-07 2011-08-01 Exelixis Inc Azetidiner som MEK inhibitorer til behandling af proliferative sygdomme
JP2008543973A (ja) * 2006-08-14 2008-12-04 シコール インコーポレイティド ペメトレキセドの中間体の調製方法
AU2007329352B2 (en) * 2006-12-07 2013-01-17 F. Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
CN101939006B (zh) * 2007-09-12 2015-09-16 吉宁特有限公司 磷酸肌醇3-激酶抑制剂化合物与化疗剂的联合以及使用方法
CN101909631B (zh) 2007-10-25 2012-09-12 健泰科生物技术公司 制备噻吩并嘧啶化合物的方法
US9042479B2 (en) 2008-10-16 2015-05-26 Qualcomm Incorporated Method and apparatus for avoiding interference between coexisting wireless systems
KR101781654B1 (ko) 2009-03-12 2017-09-25 제넨테크, 인크. 조혈 악성종양의 치료를 위한 포스포이노시티드 ３-키나제 억제제 화합물 및 화학요법제의 조합물

Also Published As

Publication number Publication date
JP2014515390A (ja) 2014-06-30
CA2835760A1 (en) 2012-12-06
WO2012164060A1 (en) 2012-12-06
RU2013154355A (ru) 2015-07-20
CN103582479A (zh) 2014-02-12
KR20140040728A (ko) 2014-04-03
EP2714046A1 (en) 2014-04-09
MX2013014151A (es) 2014-01-23
US20120308562A1 (en) 2012-12-06
AR086647A1 (es) 2014-01-15

Similar Documents

Publication Publication Date Title
BR112013028966A2 (pt) sistema fotobiorreator de calha em v e método de uso
CO6870033A2 (es) Compuestos terapéuticos y métodos de uso relacionados
BR112014016288A8 (pt) ferramenta de rotação vertebral direta e método de uso da mesma
BR112014005160A2 (pt) aparelho e método de tratamento de gás
BR112013021373A2 (pt) aparelho e método de bebida preparada
BR112013025353A2 (pt) combinações de compostos de inibidores de akt e erlotinibe e métodos de uso
BR112013030991A2 (pt) uso de gdc-0980 e método de tratamento de mesotelioma
SG11201504022RA (en) Glutamase inhibitors and method of use
DK2683731T3 (da) C4-monomethyl-triterpenoidderivater og fremgangsmåder til anvendelse deraf
CO7020870A2 (es) Anticuerpos anti-htra1 y métodos de uso
BR112014011441A2 (pt) filtro e respectivo método de operação
HK1201463A1 (en) Cd40l-specific tn3-derived scaffolds and methods of use thereof cd40l- tn3-
BR112014014213A2 (pt) agentes hemostáticos e método de utilização
BR112014002716A2 (pt) anticorpos anti-poliubiquitina e métodos de uso
BR112014009006A2 (pt) compostos heterocíclicos e métodos de uso dos mesmos
BR112012033536A2 (pt) sistema de esterilização através de chuveiro e método de utilização
DK3581199T3 (da) Fremgangsmåder til behandling eller reduktion af ødematøs fibrosklerotisk pannikulitis
BR112014001221A2 (pt) método e uso de histamina bacteriana
BR112014025507A2 (pt) formulação vesicular e método de tratamento
BR112014002804A2 (pt) revestimento e método de preparação do mesmo
BR112013034066A2 (pt) método de administração e tratamento
IL215720A0 (en) Dehumidifier and method of use thereof
FI20116338A (fi) Menetelmä ja laite näytteiden ottamiseksi ja menetelmän ja laitteen käyttö
CU24148B1 (es) Intermedios de agomelatina y método de preparación de éstos
FI20115198A (fi) Menetelmä ja laitteisto meesan polttamiseksi

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]